Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases
Supplied by PerkinElmer on Wednesday, 07 September, 2022
Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.
Learn about key strategies and innovations in this space that are enabling advanced gene therapy.
Related White Papers
Gene expression and miRNA data analysis
Automated analytical pipelines that are modular and flexible, combined with the use of...
Prevent water contamination derailing your experiments
Discover how to avoid lab water contamination. Learn about what you are up against, what to...
Streamlined set-up and access to multiple read-out options with PROTAC assays
Latest PROTAC advances raise the bar for oncology...
